Comparison
Efinopegdutide vs. Eloralintide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Metabolic
CAS no.
2055640-93-0
no data
Molecular weight
no data
no data
Half-life
115 h
no data
Sequence
modifiziertes, von Oxyntomodulin abgeleitetes Peptid, konjugiert an ein humanes IgG4-Fragment (Verlängerung der Plasma-Halbwertszeit)no data
Mechanism of action
Efinopegdutide
Efinopegdutide is an oxyntomodulin-derived peptide acting as a dual agonist at the GLP-1 and glucagon receptors with a relative potency of approximately 2:1 (GLP-1 to glucagon). The GLP-1 component mediates glucose-dependent insulin secretion and modulation of satiety; the glucagon component increases energy expenditure and hepatic fat oxidation, which is proposed to contribute to the observed reduction in liver fat. Conjugation to an IgG4 fragment prolongs the half-life and enables weekly administration.
Eloralintide
Eloralintide selectively activates amylin receptors (preferentially AMY1R) and promotes satiety. The approach targets weight loss via the amylin axis, complementary to or independent of GLP-1 agents.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
3
2
of which in humans
3
1
Effects recorded
4
2
Open conflicts
1
0
Documented adverse events
1
1
Legal status
Full entries
Frequently asked questions
- What is the difference between Efinopegdutide and Eloralintide?
- Efinopegdutide is classified as "Metabolic", while Eloralintide is classified as "Metabolic". Efinopegdutide: Efinopegdutide (MK-6024, formerly JNJ-64565111 / HM12525A) is a once-weekly dual agonist at the GLP-1 and glucagon receptors, developed by Hanmi and Merck. It has been studied for obesity and notably for metabolic liver disease (MASH/NAFLD); a phase-2 trial showed greater liver-fat reduction than semaglutide. Investigational, not approved. Eloralintide: Eloralintide is a selective, long-acting amylin receptor agonist from Eli Lilly for once-weekly subcutaneous use — under investigation for obesity, alone and combined with incretin therapy. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Efinopegdutide or Eloralintide?
- The highest available evidence level is "Human RCT" for Efinopegdutide and "Human RCT" for Eloralintide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Efinopegdutide and Eloralintide in Germany and the United States?
- Germany: Efinopegdutide — Unapproved, Eloralintide — Unapproved. United States: Efinopegdutide — Unapproved, Eloralintide — Unapproved. These are factual summaries with source and review date on the individual pages.